In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics

被引:48
作者
Alhambra, A
Cuadros, JA
Cacho, J
Gómez-Garcés, JL
Alós, JI
机构
[1] Hosp Mostoles, Dept Microbiol, Madrid 28935, Spain
[2] Hosp Univ Principe Asturias, Dept Microbiol, Madrid, Spain
[3] Hosp Univ Getafe, Dept Microbiol, Madrid, Spain
关键词
carbapenems; antibiotic susceptibility; urinary tract infections;
D O I
10.1093/jac/dkh218
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The treatment of complicated urinary tract infections may require the use of a parenteral antibiotic with potent activity against the most common urinary pathogens. Ertapenem is a broad-spectrum 1beta-methyl carbapenem with a long plasma half-life that allows administration of a single daily dose. Methods: The purpose of this work was to test the in vitro susceptibility to ertapenem, ampicillin, cefazolin, cefuroxime, cefotaxime, co-amoxiclav, piperacillin/tazobactam, imipenem, gentamicin, amikacin, fosfomycin, ciprofloxacin and co-trimoxazole of 482 strains of urinary pathogens of the family Enterobacteriaceae isolated from patients in the community of Madrid (40% from males). The distribution was as follows: Escherichia coli (n = 315), Proteus mirabilis (n = 42), Klebsiella spp. (n = 14) and AmpC-producing Enterobacteriaceae (n = 111). The strains studied were selected based on their resistance to quinolones and aminoglycosides, and their production of extended-spectrum beta-lactamases (ESBLs) or AmpC-type beta-lactamases. Results: All the strains were susceptible to ertapenem, imipenem and amikacin. The MIC90 of ertapenem ranged from a minimum of 0.03 mg/L for Proteus vulgaris and a maximum of 1 mg/L for Enterobacter spp. Ertapenem was the most active of all drugs tested in all cases. On comparing antibiotic resistance among ESBL-producing strains of E. coli (n = 35) and E. coli strains not producing ESBLs (n = 280), statistically significant differences were obtained for ciprofloxacin (P = 0.002) and gentamicin (P = 0.011). Regarding ertapenem, only a slight increase in MIC50 was seen, the value being 0.015 mg/L for strains not producing ESBLs versus 0.03 mg/L for ESBL-producing strains. Conclusions: In view of its significant antibiotic potency against antibiotic-resistant Enterobacteriaceae, ertapenem may constitute a good therapeutic alternative in urinary infections caused by these pathogens.
引用
收藏
页码:1090 / 1094
页数:5
相关论文
共 12 条
  • [1] [Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
  • [2] A review of its microbiologic, pharmacokinetic and clinical aspects
    Cunha, BA
    [J]. DRUGS OF TODAY, 2002, 38 (03) : 195 - 213
  • [3] Carbapenems:: the pinnacle of the β-lactam antibiotics or room for improvement?
    Edwards, JR
    Betts, MJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (01) : 1 - 4
  • [4] In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests
    Fuchs, PC
    Barry, AL
    Brown, SD
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (05) : 703 - 706
  • [5] In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers
    Fuchs, PC
    Barry, AL
    Brown, SD
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1915 - 1918
  • [6] In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345)
    Gill, CJ
    Jackson, JJ
    Gerckens, LS
    Pelak, BA
    Thompson, RK
    Sundelof, JG
    Kropp, H
    Rosen, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) : 1996 - 2001
  • [7] A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults
    Jimenez-Cruz, F
    Jasovich, A
    Cajigas, J
    Jiang, Q
    Imbeault, D
    Woods, GL
    Gesser, RM
    [J]. UROLOGY, 2002, 60 (01) : 16 - 22
  • [8] In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum p-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates
    Kohler, J
    Dorso, KL
    Young, K
    Hammond, GG
    Rosen, H
    Kropp, H
    Silver, LL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) : 1170 - 1176
  • [9] In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia
    Livermore, DM
    Carter, MW
    Bagel, S
    Wiedemann, B
    Baquero, F
    Loza, E
    Endtz, HP
    van den Braak, N
    Fernandes, CJ
    Fernandes, L
    Frimodt-Moller, N
    Rasmussen, LS
    Giamarellou, H
    Giamarellos-Bourboulis, E
    Jarlier, V
    Nguyen, J
    Nord, CE
    Struelens, MJ
    Nonhoff, C
    Turnidge, J
    Bell, J
    Zbinden, R
    Pfister, S
    Mixson, L
    Shungu, DL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1860 - 1867
  • [10] Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection
    Pelak, BA
    Citron, DM
    Motyl, M
    Goldstein, EJC
    Woods, GL
    Teppler, H
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) : 735 - 741